Given the recent interest in using NLRP3 inflammasome inhibitors as therapeutics against neurodegenerative diseases, and the promising outcomes of these molecules in mouse models, a better understanding on the role of cytokines in NLRP3 inflammasome activation could provide valuable insights into the pathogenesis of bvFTD and its diagnosis and treatment. This evidence concerns the gene NLRP3 and behavioral variant of frontotemporal dementia.